NYSEMKT: ATNMActinium Pharmaceuticals Inc Stock
$6.87+0.31 (+4.73%)
Updated Apr 26, 2024
ATNM Price
$6.87
Fair Value Price
N/A
Market Cap
$204.61M
52 Week Low
$4.00
52 Week High
$9.86
P/E
-4.02x
P/B
4.67x
P/S
2,695.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$81.00k
Earnings
-$46.45M
Gross Margin
100%
Operating Margin
-57,346.91%
Profit Margin
-57,346.9%
Debt to Equity
1.02
Operating Cash Flow
-$40M
Beta
0.68
Next Earnings
May 15, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ATNM Overview
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ATNM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATNM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ATNM is good value based on its book value relative to its share price (4.67x), compared to the US Biotechnology industry average (5.85x)
P/B vs Industry Valuation
ATNM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ATNM due diligence checks available for Premium users.
Be the first to know about important ATNM news, forecast changes, insider trades & much more!
ATNM News
Valuation
ATNM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.02x
Industry
14.88x
Market
41.14x
ATNM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.67x
Industry
5.85x
ATNM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATNM's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.7M
Profit Margin
0%
ATNM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ATNM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$88.4M
Liabilities
$44.5M
Debt to equity
1.02
ATNM's short-term assets ($85.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATNM's short-term assets ($85.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATNM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATNM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.4M
Investing
-$11.0k
Financing
$14.8M
ATNM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATNM vs Biotech Stocks
Actinium Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.